PyInvesting

Market research

ECX.F Epigenomics AG

F EUR Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
804K
P/E ratio
Not available
Analyst target
5.32
Dividend yield
Not available
Beta
0.87

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Epigenomics AG is currently in a long term downtrend where the price is trading 35.1% below its 200 day moving average.

From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.5.

Epigenomics AG's total revenue rose by 8.3% to $301K since the same quarter in the previous year.

Its net income has increased by 63.2% to $-3M since the same quarter in the previous year.

Finally, its free cash flow grew by 22.4% to $-2M since the same quarter in the previous year.

Based on the above factors, Epigenomics AG gets an overall score of 4/5.